Most current anticancer therapies act by inducing tumor cell stasis followed by apoptosis. HIV-1 Vpr effectively induces apoptosis of T cells after arrest of cells at a G2͞M checkpoint. Here, we investigated whether this property of Vpr could be exploited for use as a potential anticancer agent. As a potentially safer alternative to transfer of genes encoding Vpr, we developed a method to efficiently introduce Vpr protein directly into cells. Vpr packaged into HIV-1 virions lacking a genome induced efficient cell cycle arrest and apoptosis. Introduction of Vpr into tumor cell lines of various tissue origin, including those bearing predisposing mutations in p53, XPA, and hMLH1, induced cell cycle arrest and apoptosis with high efficiency. Significantly, apoptosis mediated by virion-associated Vpr was more effective on rapidly dividing cells compared with slow-growing cells, thus, in concept, providing a potential differential effect between some types of tumor cells and surrounding normal cells. This model system provides a rationale and proof of concept for the development of potential cancer therapeutic agents based on the growth-arresting and apoptotic properties of Vpr.
Most current anticancer therapies act by inducing tumor cell stasis followed by apoptosis. HIV-1 Vpr effectively induces apoptosis of T cells after arrest of cells at a G2͞M checkpoint. Here, we investigated whether this property of Vpr could be exploited for use as a potential anticancer agent. As a potentially safer alternative to transfer of genes encoding Vpr, we developed a method to efficiently introduce Vpr protein directly into cells. Vpr packaged into HIV-1 virions lacking a genome induced efficient cell cycle arrest and apoptosis. Introduction of Vpr into tumor cell lines of various tissue origin, including those bearing predisposing mutations in p53, XPA, and hMLH1, induced cell cycle arrest and apoptosis with high efficiency. Significantly, apoptosis mediated by virion-associated Vpr was more effective on rapidly dividing cells compared with slow-growing cells, thus, in concept, providing a potential differential effect between some types of tumor cells and surrounding normal cells. This model system provides a rationale and proof of concept for the development of potential cancer therapeutic agents based on the growth-arresting and apoptotic properties of Vpr.
H
IV-1 Vpr is a 96-aa protein that is expressed after HIV-1 infection. A number of functions have been ascribed to Vpr, including induction of G 2 arrest followed by apoptosis in T cells as well as other human cells (1) (2) (3) (4) (5) (6) . Vpr was found to be a strong inducer of apoptosis (5, 6) , although in some reports Vpr was shown to inhibit apoptosis (7, 8) . Vpr also is found in HIV-1 virions (9-11), and virion-associated Vpr can induce cell cycle arrest after infection in the absence of new Vpr expression (12) . Here we demonstrate apoptosis in a wide range of target cells and investigate whether the cytostatic and apoptotic effects of Vpr could be used to develop potential model strategies for cancer therapeutics.
Because of the potential safety issues involving gene transfer and constitutive expression of a gene with potent cell-arresting and apoptotic effects, we devised a strategy to transiently introduce Vpr protein into cells in the absence of a viral genome. Recently, we demonstrated that Vpr packaged within HIV-1 virions, in the absence of de novo protein synthesis, was sufficient to induce G 2 arrest (12) . We examined whether virion-associated Vpr was also capable of inducing apoptosis. This approach afforded a system in which we could examine the effects of Vpr without permanently introducing a viral genome into the host cells' genomic DNA.
Materials and Methods
Cells. HeLa and 293T cells were maintained in DMEM plus 10% BCS. SW480, XP12BESV, HT1080.ATCC, and HT1080.GTG were maintained in DMEM plus 10% FCS. SupT1 cells were maintained in Iscove's modified Dulbecco's medium (Iscove's) plus 10% FCS. LNCap cells were maintained in RPMI medium 1640 plus 10% FCS. Normal human diploid fibroblasts (ATCC CRL2076) were maintained in Iscove's plus either 10% FCS or 1%-depleted FCS. Iscove's plus 1%-depleted FCS was prepared as follows: Iscove's plus 10% FCS was sequentially passaged onto fresh cells six times. After the sixth passage the media was diluted 1:10 with fresh Iscove's without FCS, thus producing media containing 1%-depleted FCS. All cells were maintained at 37°C and 5% CO 2 .
Viral Constructs and Production of Viral Stocks. The retroviral vectors, pHR'Thy and pHR'Vpr, were produced by cloning the murine thy 1.2 and HIV-1 vpr genes, respectively, into pHR'-CMV-lacZ (13) . By oligo-directed mutagenesis, the C-terminal 64 aa of Vpr were deleted from the packaging plasmid pCMV⌬R8.2 (14) , resulting in pCMV⌬R8.2⌬Vpr. HR'Thy(VprϪ) and HR'Vpr viral stocks were produced by cotransfection of pHR'Thy or pHR'Vpr, pCMV⌬R8.2⌬Vpr, and pCMVVSV-G. The HR'Thy(Vprϩ) viral stock was produced by cotransfection of pHR'Thy, pCMV⌬R8.2, and pCMVVSV-G. Virions devoid of viral RNA were produced by cotransfection with either pCMV⌬R8.2 or pCMV⌬R8.2⌬Vpr, and pCMV-VSV-G, resulting in RNA-(Vprϩ) and RNA-(VprϪ), respectively. HIV-1 NL4 -3-thy env(-) was generated by cotransfection of pCMVVSV-G and NLthy⌬Bgl (15) . All viral stocks were produced by calcium phosphate-mediated transfection (16) Western Blot Analysis. Concentrated virus stocks were lysed in 2ϫ loading buffer and subjected to electrophoresis on SDS-15% polyacrylamide gels (12) . Western blot analysis was performed with anti-HIV-1 hyperimmune plasma (kindly provided by P. Krogstad and Y. Bryson, University of California, Los Angeles) or anti-Vpr polyclonal antibody (kindly provided by N. Landau, Salk Institute for Biological Studies, La Jolla, CA) and developed with the enhanced chemiluminescence assay (Amersham Pharmacia).
Results

HIV-1
Vpr is packaged into the virion through an association with the structural Gag protein, p6 (17, 18) . Therefore, by using a packaging plasmid expressing Gag and Vpr, we can generate virions that contain Vpr protein but do not encode Vpr within the genome. The genome of the HIV-1 retroviral vector, HR'Thy, which expresses the murine thy 1.2 gene, was copackaged to facilitate identification of infected cells. Thus, HR'Thy(VprϪ) and HR'Thy(Vpr؉) were produced by cotransfection of pHR'Thy, a packaging plasmid either encoding a truncated vpr gene (pCMV⌬R8.2⌬Vpr) or wild-type vpr gene (pCMV⌬R8.2), respectively, and a third vector expressing the vesicular stomatitis virus envelope, pCMVVSV-G. (Fig. 1a) ]. Analysis of the dead cell population confirmed that Vpr packaged into virions efficiently induced cell death (Fig. 1b) . At 72 h postinfection, 29.4% of cells infected with virions bearing Vpr were dead compared with 8.7% and 11.1% of cells either mock-infected or infected with Vpr-minus virions, respectively. The percent of dead and apoptotic cells reported reflect only that measured at a single time point. However, when the data is examined in a cumulative fashion we observe that virtually all of the cells infected with the Vprbearing virus, HR'Thy(Vprϩ), died by apoptosis. Thus virionassociated Vpr is sufficient to induce apoptosis.
Virion-Associated Vpr Within Virions Lacking a Viral Genome Induces
Apoptosis. Another concern over the use of retroviral vectors for gene delivery is the possibility of insertional mutagenesis. Therefore, we modified the above strategy to deliver Vpr within virions Western blot analysis of the viral stocks demonstrated the presence of the Gag protein, p24, and p17 (Fig. 2a) . As expected, virions made in the presence of wild-type Vpr [RNA-(Vprϩ)] contained Vpr whereas those made in the absence of Vpr [RNA-(VprϪ)] did not (Fig. 2b) .
Virions containing Vpr in the absence of a viral genome induced apoptosis as efficiently as virions containing both a vector genome and Vpr [ Fig. 3a compare RNA-(Vprϩ) (F) with Cells were either mock-infected or infected with HR'Thy (VprϪ) or HR'Thy (Vprϩ). Cell cycle arrest and apoptosis were monitored on day 2 (HT1080.6TG, HCT116) or day 3 (HeLa, SW480, HT1080.ATCC, SupT1, LNCap, XP12BESV) postinfection, determined by the time point at which maximal apoptosis was observed. wt, wild type; mt, mutant; null, unstable. The data are representative of two independent experiments. *The phenotype of the cell line was determined in ref. 28 . † The phenotype of the cell line was determined in ref. 29 . ‡ The phenotypes of the cell lines were determined as described in the text. § The phenotype of the cell line was determined in ref. 30 . HR'Thy(Vprϩ) (OE)]. As expected, control cells infected with virions without Vpr [HR'Thy(VprϪ) (Fig. 3a, f) or RNA-(VprϪ) (Fig. 3a, Ⅺ (Fig.  3a) . Quantitation of the dead cell populations confirmed the results of the apoptosis analysis (Fig. 3b) .
Exogenously added soluble Vpr has been reported to increase HIV-1 infection (19) and to affect the differentiation of rhabdomyosarcoma cells (20) . To control for the effects, if any, of exogenous Vpr, we produced genome-minus virions containing Vpr without the VSV-G envelope. Consistent with our previously published results (12) , infection of HeLa cells with non-VSV-G-enveloped virions did not result in G 2 arrest or apoptosis (data not shown). This result indicates that viral entry, presumably resulting in delivery into the cell of virion-associated Vpr, was required to induce apoptosis.
The Kinetics of Vpr-Induced Cell Death Is More Rapid Than ␥-Radiation-Induced Apoptosis. Thirty to 60 grays (3,000-6,000 rads) of ␥-radiation often are used to treat cancer in the clinical arena. Therefore, we compared the efficiency of apoptosis induced by Vpr versus a clinically relevant dose of ␥-radiation. HeLa cells infected with virions containing Vpr arrested at the G 2 ͞M border as efficiently as cells receiving 4,000 rads of ␥-radiation (Fig. 4a) . Annexin V analysis revealed that Vpr-containing virions and ␥-radiation both induced apoptosis efficiently. However, Vpr-induced apoptosis appears to occur more rapidly (Fig.  4b) , resulting in greater cumulative cell death by 72 h posttreatment (Fig. 4c) .
HIV-1 Vpr Induces Cell Cycle Arrest and Apoptosis in Multiple Tumor
Cell Lines. Many tumor cells are refractory to induction of cell cycle arrest and͞or apoptosis by standard chemotherapeutic agents. Resistance often is associated with mutations in tumor suppressor genes. p53, in particular, has been shown to be required for certain cell cycle arrest and apoptotic pathways (21) (22) (23) . We examined Vpr-induced cell cycle arrest and apoptosis in cell lines that varied in their p53 phenotype status or were deficient in DNA repair mechanisms, which are predisposing to malignancy (Table 1) . Virions bearing Vpr induced G 2 arrest and apoptotic cell death regardless of p53 phenotype status. We also examined two matched fibrosarcoma cell lines differing only in p53 genotype. HT1080.ATCC contains two wild-type p53 alleles and HT1080.6TG contains two mutant p53 alleles (24) . Virion-associated Vpr was equally proficient in inducing G 2 arrest and apoptosis in these cells regardless of the presence or absence of p53. Similarly, introduction of Vpr into tumor cell lines defective in different DNA repair mechanisms, such as mismatch repair (hMLH1) (25) and nucleotide excision repair (xeroderma pigmentosum, complementation group A) (26), resulted in G 2 arrest and apoptosis.
Vpr-Induced Apoptosis Preferentially Targets Rapidly Dividing Cells.
The effective use of cancer therapeutic agents such as radiation and chemotherapy depend on the differential effects induced in tumor cells versus normal cells. The increased sensitivity of tumor cells to genotoxic agents is likely caused by the increased and unregulated growth of these cells, thereby increasing their susceptibility to apoptosis (22) . HIV-1 Vpr's cytotoxic effects correlate with induction of G 2 arrest, suggesting that Vprinduced cell death requires entrance into G 2 (5, 6) . Because the half-life of Vpr is approximately 20 h (27), we predicted that stationary or slowly dividing cells would be less susceptible to apoptosis induced by virion-associated Vpr relative to rapidly dividing cells.
We tested this prediction by growing normal human diploid fibroblasts in either media containing 10% bovine FCS or 1%-depleted FCS. Cells grown in 10% FCS continued to divide while the growth rate of cells grown in 1%-depleted FCS was reduced (Fig. 5a ).
Cells were infected with virus bearing the VSV-G envelope and expressing de novo synthesized Vpr [HIV-1 NL4 -3Thy env(-)], with virions containing virion-associated Vpr only [HR'Thy(Vprϩ)], or with virions lacking Vpr [HR'Thy(VprϪ)]. Infection of normal diploid fibroblasts grown in either 10% FCS or 1%-depleted FCS with each of these three viruses resulted in efficient infection as evidenced by Thy 1.2 staining (Fig. 5b,  legend) . Analysis of annexin V-positive cells indicated that continuous de novo production of Vpr after infection with HIV-1 NL4 -3Thy env(-) resulted in apoptosis of virtually all cells infected regardless of their rate of division (Fig. 5 b and c , compare 10% serum and 1%-depleted serum), reinforcing the concept that continuous expression of an apoptotic gene would be detrimental to normal cell viability. In marked contrast, infection of slowly dividing fibroblasts grown in 1%-depleted FCS with virions bearing Vpr but without de novo production [HR'Thy(Vprϩ)] resulted in only 8.6% annexin V-positive cells 216 h postinfection, similar to cells infected with virions without Vpr [HR'Thy(VprϪ)] (Fig. 5c) . Infection of rapidly dividing fibroblasts grown in 10% FCS with the same Vpr-containing virus [HR'Thy(Vprϩ)] resulted in 61.5% annexin V-positive cells (Fig. 5b) , indicating that rapidly replicating cells are more sensitive to incoming Vpr delivered via virions.
Discussion
In summary, we demonstrate that Vpr is capable of inducing cell cycle arrest and apoptosis in many cancer cell lines, including those defective for some tumor suppressor genes and DNA repair genes. We further show that delivery of the Vpr protein, rather than a gene encoding Vpr, can be accomplished by taking advantage of the ability of Vpr to be packaged into virions.
Apoptosis induced by Vpr contained within virions depends on the presence of the VSV-G envelope to allow entry of virions into cells. Furthermore, virions can be produced without the presence of an infectious genome within the virion particle. The latter strategy minimizes the potential for insertional mutagenesis. If needed, one approach to further enhance safety could be to deliver Vpr in the presence of inhibitors of HIV-1 replication including reverse transcriptase and protease inhibitors. Inclusion of such inhibitors would prevent reverse transcription and viral maturation, respectively, but as we demonstrated previously, would have no effect on virion-induced cell cycle arrest (12) .
Successful treatment of malignancies in humans depends on the ability of anticancer therapies to preferentially target tumor cells, stop their replication, and kill them. We show that apoptosis induced by Vpr delivered in virions depends on continued cell division, thus providing a potential differential effect on tumor cells relative to surrounding normal cells. It remains to be tested whether virion-associated Vpr can, in fact, preferentially target tumor cells in vivo. Recent studies have suggested that some types of cancer cells may not replicate more rapidly than surrounding tissue. In contrast, some types of cancer do grow more rapidly than the normal surrounding tissue, suggesting that they may be good targets for therapy. Notably, induction of apoptosis by virions lacking a viral genome can be achieved by multiplicities of infection less than one, suggesting that virions can be produced in amounts suitable for testing in in vivo models.
The mechanism of HIV-1 Vpr-induced G 2 arrest and apoptosis remains to be elucidated, although many features of the arrest are similar to that induced by DNA damaging agents (15) . Developing a further understanding of the targets of Vpr in specific signal transduction pathways that lead to cell cycle arrest and apoptosis will be critical for developing the most effective approaches to use this property of Vpr for cancer therapeutics. There are a number of approaches, including those described here, using gene or protein delivery, which may be feasible for some types of cancer. The HIV-1 vectors described here serve as the basis for future development of more specific targeting strategies underway in multiple laboratories. Together with Vpr's preferential effects on rapidly growing cells, vectorspecific targeting strategies will provide even greater specificity for tumor cells. Thus, our results provide a proof of concept for the potential adaptation of the unique properties of Vpr in the setting of cancer.
